Junwei Su1, Stephanie Shiau2, Stephen M Arpadi3,4,5, Renate Strehlau6, Megan Burke6, Faeezah Patel6, Louise Kuhn4,5, Ashraf Coovadia6, Michael T Yin7. 1. The Department of Infectious Diseases, State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. 2. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ. 3. Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY. 4. Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY. 5. Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY. 6. Empilweni Services and Research Unit, Department of Pediatrics and Child Health, Faculty of Health Sciences, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, Johannesburg, South Africa. 7. Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY.
Abstract
OBJECTIVES: Children with HIV (CHIV) have lifetime exposure to antiretrovirals (ART); therefore, optimizing their regimens to have the least impact on fat redistribution is a priority. METHODS: This is a cross-sectional study of 219 perinatally infected CHIV and 219 HIV-uninfected controls from similar socioeconomic backgrounds in Johannesburg, South Africa. We compared total body and regional fat distribution in CHIV on suppressive ART regimens with controls and, among CHIV, between ritonavir-boosted lopinavir (LPV/r)-based and efavirenz (EFV)-based regimens. RESULTS: The mean age of the 219 uninfected children (45% girls) and the 219 CHIV (48% girls) was 7.0 and 6.4 years, respectively. CHIV had lower adjusted total body fat (P = 0.005) and lower percentage fat at the trunk (P = 0.020), arms (P = 0.001), and legs (P < 0.001) than uninfected children. CHIV on LPV/r had similar body composition as those on EFV, except for arm fat mass (P = 0.030). When stratified by sex, girls with HIV on LPV/r had lower adjusted total (P = 0.007), trunk (P = 0.002), arms (P = 0.008), legs (P = 0.048) fat mass; trunk-to-total body fat (P = 0.044); and higher legs-to-total body fat (P = 0.011) than those on EFV. CONCLUSIONS: South African CHIV receiving ART had lower global and partial fat mass and percentage fat than healthy controls. In girls with HIV with sustained virologic suppression on ART, switching from LPV/r to EFV could attenuate fat mass loss, indicating that EFV-based regimen may be a better option in this group of individuals.
OBJECTIVES: Children with HIV (CHIV) have lifetime exposure to antiretrovirals (ART); therefore, optimizing their regimens to have the least impact on fat redistribution is a priority. METHODS: This is a cross-sectional study of 219 perinatally infected CHIV and 219 HIV-uninfected controls from similar socioeconomic backgrounds in Johannesburg, South Africa. We compared total body and regional fat distribution in CHIV on suppressive ART regimens with controls and, among CHIV, between ritonavir-boosted lopinavir (LPV/r)-based and efavirenz (EFV)-based regimens. RESULTS: The mean age of the 219 uninfected children (45% girls) and the 219 CHIV (48% girls) was 7.0 and 6.4 years, respectively. CHIV had lower adjusted total body fat (P = 0.005) and lower percentage fat at the trunk (P = 0.020), arms (P = 0.001), and legs (P < 0.001) than uninfected children. CHIV on LPV/r had similar body composition as those on EFV, except for arm fat mass (P = 0.030). When stratified by sex, girls with HIV on LPV/r had lower adjusted total (P = 0.007), trunk (P = 0.002), arms (P = 0.008), legs (P = 0.048) fat mass; trunk-to-total body fat (P = 0.044); and higher legs-to-total body fat (P = 0.011) than those on EFV. CONCLUSIONS: South African CHIV receiving ART had lower global and partial fat mass and percentage fat than healthy controls. In girls with HIV with sustained virologic suppression on ART, switching from LPV/r to EFV could attenuate fat mass loss, indicating that EFV-based regimen may be a better option in this group of individuals.
Authors: Julieta Díaz-Delfín; M del Mar Gutiérrez; José M Gallego-Escuredo; Joan C Domingo; M Gracia Mateo; Francesc Villarroya; Pere Domingo; Marta Giralt Journal: Antiviral Res Date: 2011-05-17 Impact factor: 5.970
Authors: Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues Journal: Hepatology Date: 2010-07 Impact factor: 17.425
Authors: Leysa J Gomez-Sucerquia; Ana Blas-Garcia; Miguel Marti-Cabrera; Juan V Esplugues; Nadezda Apostolova Journal: Antiviral Res Date: 2012-04-24 Impact factor: 5.970
Authors: Pere Domingo; Maria del Mar Gutierrez; José Miguel Gallego-Escuredo; Ferran Torres; Maria Gracia Mateo; Joan Villarroya; Karuna Lamarca; Joan Carles Domingo; Francesc Vidal; Francesc Villarroya; Marta Giralt Journal: J Acquir Immune Defic Syndr Date: 2014-08-15 Impact factor: 3.731
Authors: Priya Bhagwat; Ighovwerha Ofotokun; Grace A McComsey; Todd T Brown; Carlee Moser; Catherine A Sugar; Judith S Currier Journal: Open Forum Infect Dis Date: 2018-11-16 Impact factor: 3.835